Key result
Inhibition of the TRPV4 ion channel is proposed as a promising therapeutic strategy to protect the alveolo-capillary barrier and prevent lethal lung edema in patients with COVID-19.
Why the study?
Does TRPV4 inhibition prevent lung edema in COVID-19 patients?
Population
COVID-19 patients with respiratory malfunction and at risk for lung edema
Design
Editorial
Authors
Loading...
TRPV4 inhibition is proposed as a novel therapeutic strategy to prevent lethal lung edema in COVID-19 by directly protecting the alveolo-capillary barrier.
Does TRPV4 inhibition prevent lung edema in COVID-19 patients?
TRPV4 inhibition is proposed as a novel therapeutic strategy to prevent lethal lung edema in COVID-19 by directly protecting the alveolo-capillary barrier.
Kuebler et al. (2020) conducted an editorial in COVID-19. TRPV4 inhibition was evaluated. Inhibition of the TRPV4 ion channel is proposed as a promising therapeutic strategy to protect the alveolo-capillary barrier and prevent lethal lung edema in patients with COVID-19.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: